NASDAQ:ZYXI Zynex (ZYXI) Stock Price, News & Analysis $7.84 -0.05 (-0.63%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.68▼$7.8950-Day Range$7.19▼$10.3152-Week Range$6.88▼$13.77Volume81,571 shsAverage Volume188,414 shsMarket Capitalization$249.12 millionP/E Ratio34.09Dividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Zynex alerts: Email Address Zynex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside78.6% Upside$14.00 Price TargetShort InterestBearish32.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 10 Articles This WeekInsider TradingBalancedInsiders Both Buying and SellingProj. Earnings Growth140.91%From $0.22 to $0.53 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.24 out of 5 starsMedical Sector294th out of 910 stocksElectromedical Equipment Industry7th out of 22 stocks 3.5 Analyst's Opinion Consensus RatingZynex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZynex has only been the subject of 2 research reports in the past 90 days.Read more about Zynex's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted32.41% of the float of Zynex has been sold short.Short Interest Ratio / Days to CoverZynex has a short interest ratio ("days to cover") of 34, which indicates bearish sentiment.Change versus previous monthShort interest in Zynex has recently decreased by 2.31%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldZynex does not currently pay a dividend.Dividend GrowthZynex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYXI. Previous Next 1.7 News and Social Media Coverage News SentimentZynex has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Zynex this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ZYXI on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynex insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $58,240.00 in company stock and sold $64,906.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.Percentage Held by Insiders52.13% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.68% of the stock of Zynex is held by institutions.Read more about Zynex's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Zynex are expected to grow by 140.91% in the coming year, from $0.22 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynex is 34.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.25.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynex is 34.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.15.Price to Book Value per Share RatioZynex has a P/B Ratio of 7.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Zynex Stock (NASDAQ:ZYXI)Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.Read More ZYXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYXI Stock News HeadlinesAugust 10, 2024 | insidertrades.comAnna Lucsok Sells 8,083 Shares of Zynex, Inc. (NASDAQ:ZYXI) StockSeptember 7 at 10:34 AM | proactiveinvestors.comZynex CEO reflects on 28 years of medical device innovation - ICYMISeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…September 6 at 5:54 PM | finance.yahoo.comIn spite of recent selling, insiders still have the largest holding in Zynex, Inc. (NASDAQ:ZYXI) with a 51% ownershipSeptember 6 at 2:21 AM | americanbankingnews.comZynex (NASDAQ:ZYXI) Stock Rating Reaffirmed by HC WainwrightSeptember 5 at 11:45 AM | markets.businessinsider.comBuy Rating Affirmed for Zynex on FDA Clearance and Solid Growth ProspectsSeptember 4 at 9:15 AM | prnewswire.comZynex to Present at the HC Wainwright Global Investment ConferenceSeptember 4 at 12:38 AM | markets.businessinsider.comZynex Receives FDA Clearance For New TensWave DeviceSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…September 3, 2024 | proactiveinvestors.comZynex pain management device TensWave achieves FDA clearanceSeptember 3, 2024 | prnewswire.comZynex Obtains FDA clearance for new Pain Management DeviceAugust 20, 2024 | proactiveinvestors.comZynex's bold expansion in patient monitoring technologies moves from vision to realityAugust 17, 2024 | finance.yahoo.comZynex's (NASDAQ:ZYXI) Returns On Capital Not Reflecting Well On The BusinessAugust 9, 2024 | benzinga.comChief Operating Officer Of Zynex Sold $199K In StockAugust 9, 2024 | finance.yahoo.comInsider Sale: COO Anna Lucsok Sells 24,875 Shares of Zynex Inc (ZYXI)August 2, 2024 | nasdaq.comWednesday 7/31 Insider Buying Report: ZYXI, HTBIJuly 31, 2024 | benzinga.comSell Alert: Daniel Moorhead Cashes Out $123K In Zynex StockJuly 26, 2024 | fool.comWhy Zynex Plunged TodaySee More Headlines Receive ZYXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/25/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:ZYXI CUSIPN/A CIK846475 Webwww.zynex.com Phone(303) 703-4906FaxN/AEmployees1,100Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$16.00 Low Stock Price Target$12.00 Potential Upside/Downside+78.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.23 Trailing P/E Ratio34.09 Forward P/E Ratio35.64 P/E GrowthN/ANet Income$9.73 million Net Margins3.12% Pretax Margin4.39% Return on Equity14.15% Return on Assets4.50% Debt Debt-to-Equity Ratio1.79 Current Ratio4.06 Quick Ratio3.22 Sales & Book Value Annual Sales$193.61 million Price / Sales1.29 Cash Flow$0.42 per share Price / Cash Flow18.83 Book Value$1.03 per share Price / Book7.61Miscellaneous Outstanding Shares31,775,000Free Float15,211,000Market Cap$249.12 million OptionableOptionable Beta0.54 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Thomas Sandgaard (Age 65)Founder, President, CEO & Chairman Comp: $992.83kMr. Daniel J. Moorhead (Age 52)Chief Financial Officer Comp: $472.61kMs. Anna Lucsok (Age 37)Chief Operating Officer Comp: $400.84kMr. Steve FoxVice President Of SalesMr. Donald GreggPresident of Zynex Monitoring SolutionsMr. Neil FrieryPresident & COO of Zynex Monitoring Solutions, Inc.More ExecutivesKey CompetitorsCuteraNASDAQ:CUTRPerspective TherapeuticsNYSE:CATXMiMedx GroupNASDAQ:MDXGEmbectaNASDAQ:EMBCNational VisionNASDAQ:EYEView All CompetitorsInsiders & InstitutionsCim LLCBought 2,508 shares on 9/6/2024Ownership: 0.137%Millennium Management LLCBought 118,615 shares on 8/15/2024Ownership: 0.935%AQR Capital Management LLCSold 67,148 shares on 8/15/2024Ownership: 0.124%Marshall Wace LLPSold 54,323 shares on 8/14/2024Ownership: 0.660%Hancock Whitney CorpSold 4,266 shares on 8/13/2024Ownership: 0.090%View All Insider TransactionsView All Institutional Transactions ZYXI Stock Analysis - Frequently Asked Questions How have ZYXI shares performed this year? Zynex's stock was trading at $10.89 at the beginning of 2024. Since then, ZYXI shares have decreased by 28.0% and is now trading at $7.84. View the best growth stocks for 2024 here. How were Zynex's earnings last quarter? Zynex, Inc. (NASDAQ:ZYXI) posted its earnings results on Thursday, July, 25th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.04. The company's revenue was up 11.0% on a year-over-year basis. What is Thomas Sandgaard's approval rating as Zynex's CEO? 81 employees have rated Zynex Chief Executive Officer Thomas Sandgaard on Glassdoor.com. Thomas Sandgaard has an approval rating of 87% among the company's employees. Who are Zynex's major shareholders? Top institutional shareholders of Zynex include Millennium Management LLC (0.93%), Rice Hall James & Associates LLC (0.74%), Marshall Wace LLP (0.66%) and Bank of New York Mellon Corp (0.61%). Insiders that own company stock include Joshua R Disbrow, Daniel J Moorhead and Anna Lucsok. View institutional ownership trends. How do I buy shares of Zynex? Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZYXI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zynex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZYXI Stock Alerts